Related Experiment Video
Updated: Mar 27, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Exploring the usability of EUCERD core indicators for rare diseases
Rita Maria Ferrelli1, Marta De Santis2, Amalia Egle Gentile2
1Ufficio Relazioni Esterne, Istituto Superiore di Sanità, Rome, Italy.
European initiatives developed 59 indicators for rare disease (RD) health services, later refined to 21 core indicators for better planning and comparability among Member States.
Area of Science:
- Public Health
- Health Services Research
- Rare Diseases Epidemiology
Background:
- The European Commission supported initiatives to develop health service indicators for rare diseases (RDs).
- The EUROPLAN project created 59 process and outcome indicators for monitoring National Plans on RDs.
- A large number of indicators posed challenges for practical application.
Purpose of the Study:
- To derive a manageable selection of core indicators from a larger set.
- To identify key indicators for orienting rare disease (RD) policies.
- To enhance knowledge sharing and comparability among European Member States regarding RDs.
Main Methods:
- A descriptive study was conducted within the "Working for RDs" Joint Action.
- The study aimed to select core indicators from the initial 59 EUROPLAN indicators.
- The selection process resulted in 21 core indicators adopted by the EU Committee of Experts on RDs.
Main Results:
- A subset of 21 core indicators was successfully derived from the initial 59 indicators.
- These core indicators were adopted by the European Union Committee of Experts on RDs in June 2013.
- The selected core indicators facilitate knowledge sharing and comparability across Member States.
Conclusions:
- The 21 core indicators provide a valuable tool for rare disease (RD) health service planning and evaluation.
- Core indicators enhance the ability of Member States to share knowledge and achieve comparability in RD policies.
- This selection represents a significant step towards more effective and coordinated rare disease management in Europe.
More Related Videos
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Related Concept Videos
Clinical Trials: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Clinically Relevant Drug Product Specifications: Methods of Establishment
Therapeutic Drug Monitoring: Affecting Factors
Clinical Trials
There are four phases in a clinical trial. A phase one...
Therapeutic Drug Monitoring: Overview and Classification